肾功能不全非ICU患者哌拉西林/他唑巴坦不同给药方案的PK/PD靶达标概率
本研究纳入49例肾功能不全非ICU患者,评估按说明书推荐剂量哌拉西林/他唑巴坦对“敏感、增加暴露(I)”病原体的PK/PD靶达标概率。群体药动学建模与模拟显示,短时输注按说明书剂量仅对保守靶标(fT60%>MIC)达标率>90%,对激进靶标(fT100%>4×MIC)达标率<15%;仅eGFR 30和40 mL/min患者增加日剂量持续输注可使激进靶标达标率>90%。
要点
- 按说明书剂量短时输注仅对保守PK/PD靶标达标率>90%。
- 对激进靶标(fT100%>4×MIC),短时输注说明书剂量各组达标率<15%。
- eGFR 30和40 mL/min患者增加日剂量持续输注可使激进靶标达标率>90%。
核心结论
- 按说明书推荐剂量给药仅足以达到保守PK/PD靶标。
- 模拟增加剂量并持续给药可达到激进PK/PD靶标。
- 对铜绿假单胞菌所致难治性严重感染,即使非ICU患者也可考虑替代给药方案。
研究设计与样本
- 纳入49例肾功能不全患者:eGFR 20-40 mL/min者20例,eGFR<20 mL/min者19例,间歇性血液透析者10例。
- 测定哌拉西林峰浓度、谷浓度及给药间期浓度。
- 主要终点为保守靶标(fT60%>MIC)和激进靶标(fT100%>4×MIC)的靶达标概率(PTA)。
- 建立群体药动学模型并进行基于模型的模拟。
主要发现
- 对保守PK/PD靶标,按说明书推荐剂量短时输注的所有患者PTA>90%。
- 对激进PK/PD靶标,按说明书剂量短时输注各组PTA<15%。
- 仅eGFR 30和40 mL/min患者增加日剂量持续输注时,激进靶标PTA>90%。
关键数值与推荐
- 保守PK/PD靶标:fT60%>MIC。
- 激进PK/PD靶标:fT100%>4×MIC。
- 按说明书推荐剂量短时输注:保守靶标PTA>90%,激进靶标PTA<15%。
- eGFR 30和40 mL/min患者增加日剂量持续输注:激进靶标PTA>90%。
临床怎么用
- 对肾功能不全非ICU患者,按说明书剂量短时输注可满足保守PK/PD靶标。
- 若需达到激进PK/PD靶标,可考虑增加日剂量并持续输注,尤其在eGFR 30和40 mL/min患者。
- 对铜绿假单胞菌所致难治性严重感染,可评估替代给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To optimize antibiotic therapy for pathogens classified as susceptible, increased exposure (I), an increased exposure of piperacillin/tazobactam (PTZ) is required. However, dosing recommendations are currently only available for patients with normal renal function. The aim of the study was to assess whether the recommended dosages of PTZ for patients with impaired renal function achieve adequate pharmacokinetic/pharmacodynamic (PK/PD) targets for pathogens classified as susceptible, increased exposure (I). METHODS: Overall, 49 patients with impaired renal function were included in this study (estimated glomerular filtration rate [eGFR] 20-40 mL/min: n = 20; eGFR <20 mL/min: n = 19; intermittent haemodialysis: n = 10). Peak, trough and between-dosing interval piperacillin concentrations were determined. The primary endpoint of the study was the probability of target attainment (PTA) for a conservative (fT 60% > minimal inhibitory concentration) and an aggressive PK/PD target (fT 100% > 4× minimal inhibitory concentration). First, a population pharmacokinetic model was developed followed by a model-based simulation. RESULTS: For the conservative PK/PD target, a PTA of >90% is achieved in all patients receiving intermittent short infusions, following the dosing recommendations outlined in the Summary of Product Characteristics (SmPC). For the more aggressive target, the PTA was <15% across all groups when using short infusions with SmPC dosing. Only continuous infusion with an increased daily dose in patients with eGFRs of 30 and 40 mL/min achieved a PTA of >90% in all patients. CONCLUSIONS: Dosing according to the SmPC is only sufficient to achieve a conservative PK/PD target. In comparison, simulating an increased dosing with continuous administration attained an aggressive PK/PD target. Offering alternative dosing regimens may be of interest for severe infections with difficult to treat foci caused by Pseudomonas aeruginosa even in non-intensive care unit patients.
引用
- Dohmann E, Hagel S, Kurlbaum M, et al. Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non-intensive care unit setting. Br J Clin Pharmacol. 2025. PMID: 40582359. doi:10.1002/bcp.70153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。